This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva says patent use was ‘legitimate’ in court appeal against EU’s Copaxone drug fine

( February 24, 2025, 09:09 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals has said it believes the European Commission misconstrued the patent system when fining the company last year for an antitrust abuse related to a multiple sclerosis drug. In pleas published today in the EU's Official Journal, Teva argues that the antitrust probe failed to establish the company's dominance on the market for the drug and "misconstrued the relevant legal and factual context of the European Patent Office system," which wrongly led investigators to conclude it had abused the "divisional patents." The company says its patent filings "were perfectly legitimate, and consistent with competition on the merits." The pleas from the Official Journal are attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login